Lucid Diagnostics (LUCD) Return on Capital Employed (2021 - 2026)
Lucid Diagnostics (LUCD) posted Return on Capital Employed of 625.43% for Q1 2026, down 129.8% on a QoQ basis from 272.16% in Q4 2025, and down 161728.0% year-over-year from N/an in Q1 2025.
Lucid Diagnostics (LUCD) Return on Capital Employed (2021 - 2026) Analysis & Trends
Lucid Diagnostics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 625.43% for Q1 2026.
- Quarterly Return on Capital Employed fell 161728.0% year-over-year to 625.43% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 625.43% (down 161728.0% YoY) and the FY2025 annual result came in at 709.35%, up 13279.0% from the prior year.
- Return on Capital Employed was 625.43% for Q1 2026 at Lucid Diagnostics, down from 272.16% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 991.86% in Q1 2025 and bottomed at 5540.8% in Q4 2023.
- A 5-year average of 636.21% and a median of 288.94% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed plunged 533260 bps — and 2024, when it soared 407063 bps.
- Lucid Diagnostics' Return on Capital Employed stood at 208.2% in 2022, then plunged by 2561 bps to 5540.8% in 2023, then soared by 73 bps to 1470.17% in 2024, then surged by 81 bps to 272.16% in 2025, then sank by 130 bps to 625.43% in 2026.
- Business Quant data shows LUCD's Return on Capital Employed at 625.43% in Q1 2026, 272.16% in Q4 2025, and 243.33% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Lucid Diagnostics | 133.09 Mn | 105.22 Mn | -325,000.00 | -625.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -625.43% |
| Dec 31, 2025 | -272.16% |
| Sep 30, 2025 | -243.33% |
| Jun 30, 2025 | -760.17% |
| Mar 31, 2025 | 991.86% |
| Dec 31, 2024 | -1,470.17% |
| Sep 30, 2024 | -319.93% |
| Jun 30, 2024 | -260.61% |
| Mar 31, 2024 | -464.34% |
| Dec 31, 2023 | -5,540.80% |
| Sep 30, 2023 | -680.59% |
| Jun 30, 2023 | -288.94% |
| Mar 31, 2023 | -334.58% |
| Dec 31, 2022 | -208.20% |
| Sep 30, 2022 | -163.15% |
| Jun 30, 2022 | -97.38% |
| Mar 31, 2022 | -77.64% |
| Dec 31, 2021 | -101.98% |